{"id":898767,"date":"2025-10-22T08:40:06","date_gmt":"2025-10-22T12:40:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/"},"modified":"2025-10-22T08:40:06","modified_gmt":"2025-10-22T12:40:06","slug":"data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/","title":{"rendered":"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN FRANCISCO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 22, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Nektar Therapeutics\u00a0(Nasdaq:\u00a0NKTR) announced today that new data from the ongoing REZOLVE-AD Phase <span class=\"xn-money\">2b<\/span> study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma &amp; Immunology (ACAAI) 2025 Annual Scientific Meeting. The meeting will be held in <span class=\"xn-location\">Orlando<\/span>, <span class=\"xn-location\">USA<\/span>, from <span class=\"xn-chron\">November 6 to 10, 2025<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg\" title=\"(PRNewsfoto\/Nektar Therapeutics)\" alt=\"(PRNewsfoto\/Nektar Therapeutics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b><br \/>\n          <i>Details of the presentation at ACAAI are as follows:<\/i><br \/>\n        <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Abstract ID: 7005<\/li>\n<li>Oral Presentation: &#8220;Rezpegaldesleukin Novel Treg-Inducing Therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase <span class=\"xn-money\">2b<\/span> Trial&#8221;<\/li>\n<li>Presenter: <span class=\"xn-person\">Jonathan Corren<\/span>, MD<\/li>\n<li>Session Title: Distinguished Industry &amp; Late-breaking Oral Abstracts &#8211; Session 2<\/li>\n<li>Presentation Date and Time: <span class=\"xn-chron\">Saturday, November 8, 2025<\/span> at <span class=\"xn-chron\">5:33 PM ET<\/span><\/li>\n<li>Location: Room W231<\/li>\n<\/ul>\n<p>The presentation will be available on Nektar&#8217;s website at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4538437-1&amp;h=310441561&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4504433-1%26h%3D875107832%26u%3Dhttp%253A%252F%252Fwww.nektar.com%252F%26a%3Dhttp%253A%252F%252Fwww.nektar.com&amp;a=http%3A%2F%2Fwww.nektar.com\" target=\"_blank\" rel=\"nofollow\">http:\/\/www.nektar.com<\/a>\u00a0under\u00a0Scientific Publications, following the formal presentation.<\/p>\n<p>\n        <b>About REZOLVE-AD Phase <span class=\"xn-money\">2b<\/span> Study<\/b>\n      <\/p>\n<p>The ongoing global Phase <span class=\"xn-money\">2b<\/span> REZOLVE-AD study (<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4538437-1&amp;h=2834392602&amp;u=https%3A%2F%2Fedge.prnewswire.com%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4504433-1%26h%3D837896647%26u%3Dhttps%253A%252F%252Fclinicaltrials.gov%252Fstudy%252FNCT06136741%253Fcond%253DAtopic%252520Dermatitis%2526intr%253DRezpegaldesleukin%2526rank%253D1%26a%3DNCT06136741&amp;a=NCT06136741\" target=\"_blank\" rel=\"nofollow\">NCT06136741<\/a>) enrolled 393 patients with moderate-to-severe atopic dermatitis who had not previously received treatment with biologic or JAK inhibitor therapies. Patients were randomized across three different dose regimens of subcutaneous rezpegaldesleukin or placebo for a 16-week induction treatment period. Following this period, rezpegaldesleukin-treated patients who achieved\u00a0EASI\u00a0percent score reductions of\u00a0<u>&gt;<\/u>50 (EASI-50) were re-randomized (1:1) to continue at the same dose level on a q4w or q12w regimen through study week 52 in a blinded maintenance period.<\/p>\n<p>The primary endpoint of the Phase <span class=\"xn-money\">2b<\/span> study is mean improvement in\u00a0EASI\u00a0score at the end of the 16-week induction treatment period. Secondary endpoints include the proportion of patients achieving Validated Investigator Global Assessment (vIGA-AD) of 0 or 1, those achieving\u00a0EASI-75, and those achieving a greater than or equal to a 4-point improvement in Itch Numeric Rating Scale (NRS). Preplanned exploratory endpoints include a full range of translational biomarker measurements and a change in asthma control questionnaire &#8211; 5 (ACQ-5) scores for patients with comorbidity of asthma.<\/p>\n<p>This trial was initiated in <span class=\"xn-chron\">October 2023<\/span> and enrolled patients across approximately 110 sites globally with: 68% enrolled and treated in <span class=\"xn-location\">Europe<\/span>, including <span class=\"xn-location\">Poland<\/span>, <span class=\"xn-location\">Bulgaria<\/span>, <span class=\"xn-location\">Germany<\/span>, <span class=\"xn-location\">Czech Republic<\/span>, <span class=\"xn-location\">Spain<\/span>, <span class=\"xn-location\">Croatia<\/span> and <span class=\"xn-location\">Hungary<\/span>; 16% enrolled and treated in <span class=\"xn-location\">the United States<\/span>; 11% enrolled and treated in <span class=\"xn-location\">Canada<\/span>; and 5% enrolled and treated in <span class=\"xn-location\">Australia<\/span>. Patient randomization was stratified based on baseline disease severity measured by vIGA-AD and geographic region. Key enrollment criteria in the study included a minimum EASI score of 16.0, a minimum Body Surface Area (BSA) of 10% and a minimum vIGA-AD of 3.\u00a0<\/p>\n<p>\n        <b>About Rezpegaldesleukin<\/b>\n      <\/p>\n<p>Autoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person&#8217;s body. A failure of the body&#8217;s self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. Rezpegaldesleukin is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. It targets the interleukin-2 receptor complex in the body to stimulate proliferation of immune-modulating cells known as regulatory T cells. By activating these cells,\u00a0rezpegaldesleukin may act to bring the immune system back into balance.<\/p>\n<p>In\u00a0February 2025, the\u00a0U.S. Food and Drug Administration\u00a0(FDA) granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In\u00a0July 2025, the FDA granted Fast Track designation for rezpegaldesleukin for the treatment of severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older who weigh at least 40 kg.<\/p>\n<p>Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. It is wholly owned by\u00a0Nektar Therapeutics.<\/p>\n<p>\n        <b>About Atopic Dermatitis<\/b>\n      <\/p>\n<p>Atopic dermatitis is the most common type of eczema, affecting approximately 30 million people in\u00a0the <span class=\"xn-location\">United States<\/span>.<sup>1<\/sup>\u00a0AD is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and in\ufb02ammation.<\/p>\n<p>\n        <b>About\u00a0Nektar Therapeutics<\/b>\n      <\/p>\n<p>Nektar Therapeutics\u00a0is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar&#8217;s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in three Phase <span class=\"xn-money\">2b<\/span> clinical trials, one in atopic dermatitis, one in alopecia areata, and one in Type 1 diabetes mellitus. Nektar&#8217;s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system&#8217;s natural ability to fight cancer, in several ongoing clinical trials.<\/p>\n<p>Nektar is headquartered in\u00a0San Francisco,\u00a0California. For further information, visit\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4538437-1&amp;h=590076837&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4476897-1%26h%3D1315373609%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4455432-1%2526h%253D29484467%2526u%253Dhttp%25253A%25252F%25252Fwww.nektar.com%25252F%2526a%253Dwww.nektar.com%26a%3Dwww.nektar.com&amp;a=www.nektar.com\" target=\"_blank\" rel=\"nofollow\">www.nektar.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4538437-1&amp;h=4286238898&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4476897-1%26h%3D1045455230%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4455432-1%2526h%253D1566066259%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D4188942-1%252526h%25253D2235361742%252526u%25253Dhttps%2525253A%2525252F%2525252Fwww.linkedin.com%2525252Fcompany%2525252Fnektar-therapeutics%2525252F%252526a%25253DLinkedIn%2526a%253DLinkedIn%26a%3DLinkedIn&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>Cautionary Note Regarding Forward-Looking Statements<\/b>\n      <\/p>\n<p>This press release contains forward-looking statements which can be identified by words such as: &#8220;will,&#8221; &#8220;develop,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;address,&#8221; &#8220;may&#8221; and similar references to future periods. Examples of forward-looking statements include, among others, statements regarding the therapeutic potential of, and future development plans for, rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are in clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv)\u00a0data reported from ongoing clinical trials are necessarily interim data only and the final results will change based on continuing observations; (v) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (vi) a Fast Track designation does not increase the likelihood that rezpegaldesleukin will receive marketing approval in\u00a0the <span class=\"xn-location\">United States<\/span>; (vii) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (viii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on\u00a0August 8, 2025. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>\n        <b>For Investors:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Vivian Wu<\/span><br \/>\n        <br \/>\n        <a href=\"mailto:VWu@nektar.com\" target=\"_blank\" rel=\"nofollow\">VWu@nektar.com<\/a>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Corey Davis<\/span>, Ph.D.<br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:cdavis@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">cdavis@lifesciadvisors.com<\/a>\u00a0<br \/>212-915-2577<\/p>\n<p>Ahu Demir, Ph.D.<br \/>LifeSci Advisors, LLC<br \/><a href=\"mailto:ademir@lifesciadvisors.com\" target=\"_blank\" rel=\"nofollow\">ademir@lifesciadvisors.com<\/a>\u00a0<br \/>212-915-3820<\/p>\n<p>\n        <b>For Media:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Jonathan Pappas<\/span><br \/>\n        <br \/>LifeSci Communications<br \/>857-205-4403<br \/><a href=\"mailto:jpappas@lifescicomms.com\" target=\"_blank\" rel=\"nofollow\">jpappas@lifescicomms.com<\/a>\u00a0<\/p>\n<p>1. Eczema stats.\u00a0National Eczema Association\u00a0(2022,\u00a0September 27).\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4538437-1&amp;h=842042490&amp;u=https%3A%2F%2Fnationaleczema.org%2Fresearch%2Feczema-facts%2F&amp;a=https%3A%2F%2Fnationaleczema.org%2Fresearch%2Feczema-facts%2F\" target=\"_blank\" rel=\"nofollow\">https:\/\/nationaleczema.org\/research\/eczema-facts\/<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=SF03805&amp;sd=2025-10-22\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting-302590927.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting-302590927.html<\/a><\/p>\n<p>SOURCE  Nektar Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF03805&amp;Transmission_Id=202510220800PR_NEWS_USPR_____SF03805&amp;DateId=20251022\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN FRANCISCO , Oct. 22, 2025 \/PRNewswire\/ &#8212; Nektar Therapeutics\u00a0(Nasdaq:\u00a0NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma &amp; Immunology (ACAAI) 2025 Annual Scientific Meeting. The meeting will be held in Orlando, USA, from November 6 to 10, 2025. Details of the presentation at ACAAI are as follows: Abstract ID: 7005 Oral Presentation: &#8220;Rezpegaldesleukin Novel Treg-Inducing Therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial&#8221; Presenter: Jonathan Corren, MD Session Title: Distinguished Industry &amp; Late-breaking Oral Abstracts &#8211; Session 2 Presentation &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898767","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO , Oct. 22, 2025 \/PRNewswire\/ &#8212; Nektar Therapeutics\u00a0(Nasdaq:\u00a0NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma &amp; Immunology (ACAAI) 2025 Annual Scientific Meeting. The meeting will be held in Orlando, USA, from November 6 to 10, 2025. Details of the presentation at ACAAI are as follows: Abstract ID: 7005 Oral Presentation: &#8220;Rezpegaldesleukin Novel Treg-Inducing Therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial&#8221; Presenter: Jonathan Corren, MD Session Title: Distinguished Industry &amp; Late-breaking Oral Abstracts &#8211; Session 2 Presentation &hellip; Continue reading &quot;Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T12:40:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting\",\"datePublished\":\"2025-10-22T12:40:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/\"},\"wordCount\":1397,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/Nektar_Logo_v1.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/\",\"name\":\"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/Nektar_Logo_v1.jpg\",\"datePublished\":\"2025-10-22T12:40:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/Nektar_Logo_v1.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1390052\\\/Nektar_Logo_v1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO , Oct. 22, 2025 \/PRNewswire\/ &#8212; Nektar Therapeutics\u00a0(Nasdaq:\u00a0NKTR) announced today that new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell (Treg) proliferator, in atopic dermatitis has been accepted for a late-breaking oral abstract presentation at the American College of Allergy, Asthma &amp; Immunology (ACAAI) 2025 Annual Scientific Meeting. The meeting will be held in Orlando, USA, from November 6 to 10, 2025. Details of the presentation at ACAAI are as follows: Abstract ID: 7005 Oral Presentation: &#8220;Rezpegaldesleukin Novel Treg-Inducing Therapy Demonstrates Efficacy in Atopic Dermatitis and Asthma in Phase 2b Trial&#8221; Presenter: Jonathan Corren, MD Session Title: Distinguished Industry &amp; Late-breaking Oral Abstracts &#8211; Session 2 Presentation &hellip; Continue reading \"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-22T12:40:06+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting","datePublished":"2025-10-22T12:40:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/"},"wordCount":1397,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/","name":"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg","datePublished":"2025-10-22T12:40:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1390052\/Nektar_Logo_v1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/data-from-rezolve-ad-phase-2b-study-for-rezpegaldesleukin-accepted-for-late-breaking-oral-abstract-presentation-at-acaai-2025-annual-scientific-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898767"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898767\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}